2026 IOTOX Symposium: Delivering What Matters - Patient-Centered through IOTOX Translational Science

This symposium is designed to create a space where experts from different backgrounds can connect and learn from each other. The focus is on the latest research and clinical practices related to immunotherapy toxicities. Participants will hear from leaders in the field, explore new technologies, and dive into practical strategies for managing complex cases. The goal is to turn cutting-edge science into everyday solutions that improve care and outcomes for patients dealing with immune-related side effects.

Call for Abstracts
We invite faculty, trainees and staff to submit abstracts in the areas of clinical, translational, and basic science research.

Abstract Timeline: 

Call for abstracts - Nov. 3, 2025

Abstract Submission Deadlines:

Jan. 2, 2026: Deadline for Oral Presentation consideration

Feb. 2, 2026: Deadline for Poster Presentation consideration only

Notification to submitters - Feb. 15, 2026

Poster session - Apr. 24, 2026

Oral presentations – Apr. 25, 2026

Click here to submit

1. Develop treatment plans that follow current guidelines for managing immunotherapy toxicities.
2. Find and use national society recommendations to guide care decisions.
3. Apply IOTOX guidelines that have been reviewed and approved by both oncologists and internal medicine experts.
4. Evaluate complex patient cases and tailor treatment plans to meet individual needs.
5. Use IOTOX protocols across the care team to ensure coordinated and effective care.

A Hybrid Live Streaming Course

The 2026 IOTOX Symposium will begin at 1:30 PM, Friday, April 24, and will adjourn at 3:35 PM, Saturday, April 25, 2026. (NOTE: All time is Central Standard Time (CST). 

Location: Zayed Building (6565 MD Anderson Blvd), Floor 2, conference center
Parking: Garage 10, 6700 MD Anderson Blvd.

ASPIRE Conference - Optional Non-CE Accredited 1/2 Day:
Since its launch in March 2024, the National Alliance for Support and Prevention of Immune-Related Adverse Events (ASPIRE) has rapidly expanded to more than 500 members from medical communities across the country. This consortium has spearheaded multiple high-impact initiatives that have advanced clinical care, education, and research in immune-related adverse events (irAEs).

Our Annual ASPIRE Conference, hosted on a rotating basis by member institutions, has become the consortium’s flagship event—uniting leaders from academia, industry, and patient advocacy to share insights, foster collaboration, and accelerate progress in the field.

This year marks the third consecutive ASPIRE Conference hosted by MD Anderson, continuing our strong tradition of leadership and commitment to the mission.

The 2026 ASPIRE (Alliance for Support and Prevention of Immune-Related adverse Event). Non-CE accredited
April 24, Friday, 8:00 AM – 12:20 PM
Location: Zayed Building

When registering, you must choose to attend in person or to attend via Zoom

REGISTRATION FEES

Telephone registrations are not accepted.

We accept the following forms of payment:
Credit Cards (MasterCard, VISA, and American Express)
Check (Payable to The University of Texas MD Anderson Cancer Center; through U.S. banks only)

Mail checks to:
Continuing Professional Education – Unit 1781
The University of Texas MD Anderson Cancer Center
P.O. Box 301407
Houston, Texas 77230-1407

When registering online a receipt (confirmation letter) will be automatically emailed to the e-mail address you list on the registration form. 

Refund/Cancellation Policy
The registration fee, minus a $25 administration-handling fee, is refundable if a written request is received on or before March 24, 2026 for both activities. No refunds will be granted after these dates. The request for a registration refund must include the tax identification number of the company or institution if registration was paid by a company or institution check. 

The Department of Continuing Professional Education (CPE), reserves the right to cancel activities prior to the scheduled date, if low enrollment or other circumstances make it necessary. Each registrant will be notified by mail, e-mail, or at the phone or fax numbers given on the registration form.  In case of activity cancellation, the liability of the CPE is limited to the registration fee. CPE will refund the full registration fee. 

CPE reserves the right to limit the number of participants in an activity and is not responsible for any expenses incurred by an individual whose registration is not confirmed and for whom space is not available. 

Special Assistance or Additional Information
Contact Continuing Professional Education / Activity Management at 713-792-2223 or 866-849-5866. You may also email CPE at [email protected].  

Ground Transportation:
Houston is served by two airports: George Bush Intercontinental (IAH) and William P. Hobby (HOU). The following ground transportation options are available to and from the airports to the Texas Medical Center:

• Rideshare: Uber and Lyft

• Taxicabs: Yellow Cab (713-236-1111) and Fiesta Cab (713-225-2666)

• Airport Shuttles: Most hotels near the Medical Center offer shuttle service; confirm with your hotel directly.

• Rental Cars: Available at both airports

Evaluation:
A course evaluation tool will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.  The survey link will be provided during the review course.

In support of improving patient care, The University of Texas MD Anderson Cancer Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Designation
The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 9.00 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The University of Texas MD Anderson Cancer Center designates this live activity will award 9.00 Nursing Contact Hour(s)Credit Designation

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 9.00 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participant completion data will be shared with and transmitted to the ACCME on the participant’s behalf.  In order to receive MOC points, you must pass the post-test with a score of 70% or higher. 

The University of Texas MD Anderson Cancer Center has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 9.00 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

View the accessibility policy for The University of Texas MD Anderson Cancer Center.

The University of Texas MD Anderson Cancer Center complies with all requirements of the identified accrediting body  (ACCME, ANCC, ACPE). Disclosure of speakers, faculty members, planning committee members and their commercial relationships will be shared with learners prior to the educational activity.

Mitigation of Relevant Financial Relationships

The University of Texas MD Anderson Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Member Information

Role in activity

Nature of Relationship(s) / Name of Ineligible Company(s)

Kristen Pauken, PhD
Assistant Professor
MD Anderson Cancer Center

Activity Co-Director

Consulting Fee-Guardant Health (Relationship has ended)

Ajay Sheshadri, MD
Assistant Professor
The University of Texas MD Anderson Cancer Center

Activity Co-Director

Consulting Fee-ADC Therapeutics (Relationship has ended)|Advisor-Tract Bio|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Sanofi US (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Lyell Immunopharma (Relationship has ended)|Consulting Fee-Pfizer Inc.|Consulting Fee-Biohaven, Inc.|Consulting Fee-Pulmoctect, Inc.

Reyvian Mason, Other
MD Anderson

Activity Coordinator

Nothing to disclose

Bilal A. Siddiqui, MD
Assistant Professor
The University of Texas MD Anderson Cancer Center

Activity Director

Advisor-Amgen Inc.|Advisor-Bayer HealthCare Pharmaceuticals, Inc.|Advisor-Pfizer Inc.|Advisor-Johnson & Johnson (any division)|Grant or research support-Amgen Inc.|Grant or research support-Johnson & Johnson (any division)|Grant or research support-Regeneron Pharmaceuticals, Inc.

Bruno P. Granwehr, MD
Professor, Infectious Diseases
The University of Texas MD Anderson Cancer Center

CE Reviewer

Nothing to disclose

Mianen Sun, PhD
Director, Research Planning and Development
MD Anderson Cancer Center

CE Reviewer

Nothing to disclose

Eric Gagneaux
Continuing Education Planner
MD Anderson Cancer Center

CPE Planner

Nothing to disclose

Marian Taylor, DNP
Continuing Education Specialist
MD Anderson Cancer Center

Nurse Planner

Nothing to disclose

Stephane Champiat, MD, PhD
The University of Texas MD Anderson Cancer Center

Planning Committee Member

Advisor-AstraZeneca US (Relationship has ended)|Advisor-Amgen Inc. (Relationship has ended)|Advisor-Bayer HealthCare Pharmaceuticals, Inc. (Relationship has ended)|Advisor-Byondis (Relationship has ended)|Advisor-Celanese|Advisor-Compugen (Relationship has ended)|Advisor-Beigene (Relationship has ended)|Advisor-Guardant|Advisor-Genmab (Relationship has ended)|Advisor-Mariana Oncology (Relationship has ended)|Advisor-Mima Health|Advisor-nanobiotix (Relationship has ended)|Advisor-Nexctcure (Relationship has ended)|Advisor-Oncovita (Relationship has ended)|Advisor-Pharma Mar|Advisor-Replimune (Relationship has ended)|Advisor-Takeda (Relationship has ended)|Advisor-Tatum Bioscience (Relationship has ended)|Advisor-UltraHuman8 (Relationship has ended)|Honoraria-Amgen Inc. (Relationship has ended)|Honoraria-Bristol-Myers Squibb Company (Relationship has ended)|Honoraria-Eisai, Inc. (Relationship has ended)|Honoraria-Merck KGaA (Relationship has ended)|Honoraria-Merck Sharp & Dohme Corp. (any division) (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-Avacta (Relationship has ended)|Grant or research support-AbbVie Inc. (Relationship has ended)|Grant or research support-Amgen Inc. (Relationship has ended)|Grant or research support-AstraZeneca US|Grant or research support-Boehringer Ingelheim (Relationship has ended)|Grant or research support-Bolt Biotherapeutics (Relationship has ended)|Grant or research support-Centessa Pharmaceuticals (Relationship has ended)|Grant or research support-Cytovation (Relationship has ended)|Grant or research support-Eisai, Inc. (Relationship has ended)|Grant or research support-Exelixis|Grant or research support-GlaxoSmithKline (Relationship has ended)|Grant or research support-Imcheck Therapeutics (Relationship has ended)|Grant or research support-Immucocore (Relationship has ended)|Grant or research support-Kumquat Biosciences|Grant or research support-Marengo|Grant or research support-Molecular Partners (Relationship has ended)|Grant or research support-Merck Sharp & Dohme Corp. (any division) (Relationship has ended)|Grant or research support-OncoC4|Grant or research support-Ose Immunotherapeutics (Relationship has ended)|Grant or research support-Owkin|Grant or research support-Pfizer Inc.|Grant or research support-Pheast|Grant or research support-Pierre Fabre (Relationship has ended)|Grant or research support-Replimune (Relationship has ended)|Grant or research support-Roche (Relationship has ended)|Grant or research support-Sanofi Genzyme (Relationship has ended)|Grant or research support-Seagen (Relationship has ended)|Grant or research support-Sotio (Relationship has ended)|Grant or research support-Transgene (Relationship has ended)|Grant or research support-Trutino Biosciences

Jianjun Gao, MD
Dr
MD Anderson Cancer Center

Planning Committee Member

Grant or research support-Summit Therapeutics

Zita Lim, Other, PA-C
Physician Assistant
The University of Texas MD Anderson Cancer Center

Planning Committee Member

Honoraria-Exelixis (Relationship has ended)

Seyed Javad M. Moghaddam, MD
Associate Professor
The University of Texas MD Anderson Cancer Center

Planning Committee Member

Grant or research support-Boehringer Ingelheim (Relationship has ended)

Roza Nurieva, PhD
Professor
The University of Texas MD Anderson. Cancer Center

Planning Committee Member

Nothing to disclose

Nicolas Palaskas, MD
Assistant Professor
MD Anderson Cancer Center

Planning Committee Member

Consulting Fee-Kiniksa Pharmaceuticals|Honoraria-Scripps (Relationship has ended)|Consulting Fee-Replimmune

Sumit K. Subudhi, MD
Associate Professor
UT MD Anderson Cancer Center

Planning Committee Member

Nothing to disclose

Yinghong Wang, MD
Professor, Gastroenterology Hepation & Nutrition
The University of Texas MD Anderson Cancer Center

Planning Committee Member

Consulting Fee-Sorriso Pharma (Relationship has ended)|Consulting Fee-MabQuest (Relationship has ended)|Consulting Fee-AzurRx (Relationship has ended)|Consulting Fee-Janssen Biotech, Inc.|Consulting Fee-IOTA (Relationship has ended)|Consulting Fee-Biontech|Consulting Fee-Kanvas Bio (Relationship has ended)|Consulting Fee-ilyapharma (Relationship has ended)|Consulting Fee-Mallinckrodt Pharma (Relationship has ended)|Consulting Fee-Thornhill|Advisor-AbbVie Inc.

Registration Coming Soon!!